AstraZeneca

A fixed-duration venetoclax-based regimen for first-line chronic lymphocytic leukemia (CLL) treatment results in lower long-term health care costs compared to continuous Bruton tyrosine kinase inhibitor (BTKi) treatment, with an approximate $8000 decrease in costs 6 months post-fixed-duration period. The study, based on Medicare claims data from 2016 to 2021, found similar all-cause costs during the first 12 months for both treatments but a significant drop in costs for the venetoclax-based regimen in the subsequent 6 months, largely due to the absence of prescription drug costs.

89% of U.S. cancer centers faced chemotherapy drug shortages, including etoposide, crucial for extensive-stage small-cell lung cancer (ES-SCLC). In Canada, etoposide shortages from 2018-2020 led to a 'natural experiment' evaluating alternative treatments, revealing increased hospitalizations and shorter progression-free survival. The study suggested clinical practice guidelines for drug shortages and future research on their socioeconomic impacts. Meanwhile, a Japanese study on durvalumab plus carboplatin and etoposide for ES-SCLC patients with poor performance status showed promising tolerability and efficacy.

TEZSPIRE (tezepelumab) showed significant reduction in nasal polyp size and congestion in Phase III WAYPOINT trial for chronic rhinosinusitis with nasal polyps (CRSwNP), offering potential new treatment.

Trump's potential control of both branches of government could ease biopharma industry pressures, including FTC scrutiny on M&A and Medicare negotiation repeal, but may also introduce unpredictability with potential high turnover at FDA and fewer drug approvals.

AstraZeneca and Amgen's Tezspire, approved for severe asthma, showed reduction in nasal polyp size and improved congestion in Phase III, potentially leading to a second indication.

Researchers developed a risk algorithm to predict acute kidney injury (AKI) from cisplatin, a cancer treatment. The study, involving 24,717 patients, created a risk score using nine clinical variables, showing higher accuracy and generalizability than previous models. The tool aids in assessing individual risk for AKI, guiding treatment decisions.

The article discusses the importance of enabling JavaScript for optimal app performance.

AstraZeneca and Amgen's Tezspire showed efficacy in reducing nasal congestion and nasal polyps in a Phase 3 trial for chronic rhinosinusitis. Jazz Pharmaceuticals plans to start an early-stage study for narcolepsy treatment JZP441 in 2024. Geron secured $250 million, potentially $375 million, for its myelofibrosis drug Rytelo. Aditum Bio and Leads Biolabs formed Oblenio Bio to develop a T cell engager for autoimmune diseases. Gilead Sciences halted Trodelvy development in second-line non-small cell lung cancer, resulting in a $1.8 billion write-down. Avid Bioservices is being taken private by GHO Capital Partners and Ampersand Capital Partners in a $1.1 billion deal.

The Phase III WAYPOINT trial showed AstraZeneca and Amgen’s Tezspire significantly reduced nasal polyp size and congestion in chronic rhinosinusitis patients, offering a potential new treatment option.